Viamet Receives Fast Track Designation from the FDA for VT-1129 for the Treatment of Cryptococcal Meningitis

Viamet Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for VT-1129 for the treatment of cryptococcal meningitis, a life-threatening fungal infection of the membranes covering the brain and spinal cord. VT-1129, an orally available inhibitor of fungal CYP51, has also received orphan drug designation for the treatment of cryptococcal meningitis and has been designated a Qualified Infectious Disease Product (QIDP) by the FDA.